Skip to main content
. 2013 Nov 14;110(1):63–70. doi: 10.1038/bjc.2013.711

Figure 3.

Figure 3

DETT protects IκBα in a manner different from bortezomib. RPMI-8226 and OCI-My5 cells were treated with DETT (0, 15, or 30 μM) or bortezomib (BZ, 20 nM) for 24 h, and whole-cell lysates were then prepared to isolate the nuclear and cytosolic fragments for western blotting assays against specific antibodies. (A) Expression of p-p65, p65 and p50 in the cytosol and nuclear fragments. (B) Expression of p-IκBα and IκBα in the whole cell lysates.